WIXBIO Inactivated Mycoplasma synoviae and Mycoplasma gallisepticum Vaccine (MS+MG) – Prevention and Control Guidelines

Mycoplasma synoviae (MS) and Mycoplasma gallisepticum (MG) are major avian pathogens severely impacting poultry health and productivity. According to recent data, MS+MG co-infection rates in commercial flocks exceed 40%, leading to significant economic losses.

The WIXBIO Inactivated MS+MG Vaccine is formulated with dual inactivated strains and an oil adjuvant to provide broad-spectrum, long-term protection against both pathogens. This guideline draws on evidence from major publications within the last 5 years and the biological features of MS and MG to present optimal vaccination strategies. It also outlines recommended immunization schedules and integrated control measures for precise immunization and effective prevention of recurrence.

Pathogen Characteristics and Current Epidemiology

1. Pathogen Profile
   • MS: Highly adept at establishing latent infections; colonizes the respiratory mucosa and disseminates hematogenously to joints, liver, spleen, and reproductive tract. Resistance to tylosin exceeds 70%.
   • MG: Primarily induces respiratory disease; readily transmitted horizontally; long incubation period (2–4 weeks); resistant to heat and low pH.
   • Co-infection: Synergistic pathogenesis markedly exacerbates arthritis; PCR surveys indicate co-infection rates >50% in affected flocks.
2. In 2025, surveillance in central and eastern China found that positivity rates for MS+MG in broilers and layers continue to rise. Recurrence rates now reach 30%, driven mostly by circulating resistant strains and inadequate biosecurity. Clinical impacts include lameness, synovial effusion, a 10–20% drop in egg production, and a 5–10% increase in deaths from secondary Escherichia coli infections.

Primary Causes of Recurrence and Rationale for Vaccination

1. Persistent latent infection: Antibiotics fail to eliminate respiratory colonization (carrier rate >30%). Vaccination stimulates mucosal sIgA and cell-mediated immunity, blocking the establishment of infection.
2. Escalating antimicrobial resistance: Conventional drugs losing efficacy; polypharmacy increases risk. Inactivated vaccines provide antibody-independent protection and reduce selection pressure for resistance.
3. Transmission gaps: Failure to interrupt vertical and horizontal spread. Combined vaccination and biosecurity establishes an effective immune barrier.

The WIXBIO MS+MG vaccine was developed specifically for prevalent resistant field strains. It provides at least 90% protection and reduces recurrence by about 80%.

Key Features of WIXBIO Inactivated MS+MG Vaccine

1. Advanced manufacturing: High-density cell suspension culture of MS-H and MG-F strains followed by double inactivation; antigen purity >95%, free of extraneous proteins.
2. The imported mineral oil adjuvant is designed to promote balanced Th1/Th2 immune responses. It supports neutralizing antibody titers of at least 1:512 and boosts cell-mediated immunity by at least 30%.
3. Broad-spectrum, long-duration protection: Effective against heterologous MS and MG field isolates; ≥95% protection from day 21 post-vaccination, lasting at least 6 months.
4. Excellent safety profile: No live organisms, minimal injection-site reactions; suitable for both broilers and layers/breeders.

Recommended Immunization Schedules

1. Broilers

7–10	WIXBIO MS+MG inactivated vaccine	0.3–0.5	Intramuscular (breast)
21–28	WIXBIO MS+MG + ND/IB bivalent inactivated vaccine	0.5	Intramuscular (breast)

2. Layers and Breeders

7–10	WIXBIO MS+MG + AI/IBD inactivated vaccine	0.3	Subcutaneous (neck)
40	WIXBIO MS+MG + ND/IB inactivated vaccine	0.5	Intramuscular
90–100	WIXBIO MS+MG + EDS/REO inactivated vaccine	0.5	Intramuscular

Store the vaccine at 2–8°C (refrigerated) and do not freeze it.

• Pre-use preparation: Warm the vaccine to 25–30°C in a 40°C water bath for 30 minutes, then shake thoroughly.
• After vaccination, at 21 days, sample 20–30 birds. Use ELISA to verify that the average antibody titer is at least 1:128.

Therapeutic Support Protocols (Vaccine-Adjunct)

1. Acute phase (first 7 days) Preferred regimen: Tiamulin via drinking water (5–7 days) + WIXBIO MS+MG hyperimmune serum/yolk antibody (1 mL/kg body weight, intramuscular). Supporting evidence (2022): Combined therapy achieves bacterial clearance >85%.
2. During the consolidation phase (about 14 days), support mucosal repair with astragalus polysaccharides (100 g per ton of feed) and Clostridium butyricum. For severely affected flocks, give a booster vaccination with WIXBIO MS+MG 14 days after the primary immunization.

Contraindications: Avoid drugs with high resistance (e.g., lincomycin). Withhold water 1–2 hours prior to medicated water administration.

Integrated Control Measures

1. Biosecurity: 14-day downtime between flocks; terminal disinfection with 0.5% glutaraldehyde; source only MS- and MG-free chicks.
2. Surveillance: Collect synovial fluid or tracheal swabs within 3 days of clinical signs for PCR testing.
3. Culling: Immediately remove and euthanize severely affected or deformed birds.

Field Case Studies

For example, a 50,000-bird broiler operation vaccinated at 7 days of age with WIXBIO MS+MG reached serum antibody titers of 1:256 by day 21. The recurrence of synovitis dropped from 25% to 3%, lowering overall losses by 40%.

Control (unvaccinated) farm: Persistent resistant infections; mortality reached 10%.

Conclusion

The WIXBIO Inactivated MS+MG Vaccine is a core tool for controlling recurrent MS+MG co-infections. When used with antimicrobial therapy, nutritional support, and biosecurity, it establishes an effective control strategy. Recent data confirm that precise vaccination can reduce recurrence by up to 80%. Implementation should be supervised by veterinarians to ensure maximum protection and farm profitability.